The Largest Randomised Study to Date Points to Low Ipsilateral Breast Tumour Relapse Rates Regardless of Delivering the Boost Sequentially or Simultaneously
Findings from the IMPORT HIGH study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1586 results
Robust and Durable Clinical Activity of Tepotinib in Patients with METex14-Skipping NSCLC
Findings from the VISION study
Intracranial Efficacy of Pembrolizumab in Patients with Brain Metastases
Findings from the phase II study
Luspatercept Improves the Rate of RBC Transfusion Independence Compared with Epoetin Alfa in ESA-naive Patients with Lower-Risk MDS
Findings from the COMMANDS study
One-Time Infusion of Lisocabtagene Maraleucel for Patients with Relapsed or Refractory CLL or SLL After Progression to BTK Inhibitor and Venetoclax Failure
Findings from the TRANSCEND CLL 004 study
Concurrent Chemoradiotherapy Followed by Adjuvant Cisplatin-Gemcitabine for the Treatment of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
Findings from the randomised phase III study
A Single Ciltacabtagene Autoleucel Infusion Results in a Lower Risk of Disease Progression or Death in Patients with Lenalidomide-Refractory Multiple Myeloma
Findings from the CARTITUDE-4 study
Adding Atezolizumab to Cabozantinib Fails to Improve Clinical Outcomes and Increases Toxicity in Patients with RCC and Disease Progression on or After Previous ICI Treatment
Findings from the CONTACT-03 study
Clinical Benefit and Safety of Encorafenib Plus Binimetinib in Treatment-Naïve and Previously Treated Patients with BRAFV600-mutated Metastatic NSCLC
Findings from the PHAROS study
EMA Recommends Extension of Indications for Nivolumab
New indication concerns a combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence
Zanidatamab Demonstrates Meaningful Clinical Benefit with a Manageable Safety Profile in Patients with Treatment-Refractory, HER2-positive Biliary Tract Cancer
Findings from the pivotal HERIZON-BTC-01 study
Talazoparib Plus Enzalutamide Improves rPFS Over Placebo Plus Enzalutamide in First-Line Treatment for Patients with mCRPC
Findings from the TALAPRO-2 study